Therapy Areas: Oncology
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
9 October 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Friday that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to...
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
9 October 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has approved Tecentriq (...
Alpheus Medical starts new clinical trial of PoMA therapy in butterfly glioblastoma
9 October 2026 - Clinical-stage biotechnology company Alpheus Medical Inc announced on Thursday the launch of a new clinical trial evaluating its investigational Porphyrin Metabolite Activation (PoMA)...
Sophos IRB and ALCMI partner to support lung cancer research
9 October 2026 - Sophos IRB Inc, an independent, oncology-focused central institutional review board, announced on Thursday a strategic partnership with the Addario Lung Cancer Medical Institute (ALCM...
Northwest Biotherapeutics and NHSBT collaborate to support production of DCVax-L
9 October 2026 - Northwest Biotherapeutics (NWBio) (OTCQB:NWBO), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Thursday a collaboration ...
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
8 October 2026 - Clinical-stage biopharmaceutical company Vir Biotechnology Inc (Nasdaq:VIR) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation to ...